Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial.

ABSTRACT: This study evaluated the efficacy and safety of 26?weeks of twice-daily (BID) alogliptin?+?metformin fixed-dose combination (FDC) therapy in Asian patients with type 2 diabetes. Patients aged 18 to 75?years with hemoglobin A1c (HbA1c) of 7.5% to 10.0% after ?2?months of diet and exercise and a 4-week placebo run-in were enrolled. Eligible patients were randomized (1:1:1:1) to placebo, alogliptin 12.5?mg BID, metformin 500?mg BID or alogliptin 12.5?mg plus metformin 500?mg FDC BID. The primary endpoint was change in HbA1c from baseline to end of treatment (Week 26). In total, 647 patients were randomized. The least-squares mean change in HbA1c from baseline to Week 26 was -0.19% with placebo, -0.86% with alogliptin, -1.04% with metformin and -1.53% with alogliptin?+?metformin FDC. Alogliptin?+?metformin FDC was significantly more effective ( P ?

SUBMITTER: Ji L 

PROVIDER: S-EPMC5412676 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature